CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
Bendamustine-based first-line chemotherapy was associated with fewer hospitalizations and fewer toxic events compared with cyclophosphamide-based regimens.
Long-term follow-up confirmed preliminary results suggesting that rituximab maintenance following treatment with R-CHOP is safe and effective.
Overall survival at 5 years was 100% with the reduced-intensity conditioning regimen compared with 48.5% with the myeloablative conditioning regimen.
For older patients with follicular lymphoma, receipt of appropriate therapy for this disease was associated with a significant gain in overall survival.
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
Progression-free survival was superior with lenalidomide compared with placebo, while health-related quality of life was similar and did not change during the study.
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
Severe comorbidities were found to be associated with increased all-cause and lymphoma-specific mortality compared with patients without comorbidities.
Researchers characterized outcomes for enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, and peripheral gamma delta T-cell lymphoma.
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
In phase 2 analyses, patients receiving polatuzumab vedotin experienced improved overall and progression-free survival compared with patients in the control arm.
Facilities that treated more patients with classical Hodgkin lymphoma annually had lower overall mortality rates.
This study used atomic absorption spectrometry to evaluate the levels of trace metals in specimens of patients with lymphoma compared with healthy controls.
Patients with Hodgkin lymphoma who were deficient for vitamin D experienced reduced progression-free and overall survival.
Imaging mass cytometry can characterize the spatial landscape of different types of immune cells in the tumor microenvironment of tissue specimens.
The combination warrants no further study in these patients.
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
Researchers created a discrete event simulation model to assess the potential influence of wait time ranging from 1 to 9 months on CAR-T therapy efficacy.
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
Patients referred to the clinic were diagnosed nearly 2 weeks faster compared with historical controls.
Significant associations were found between primary central nervous system lymphoma and systemic lupus erythematosus, myasthenia gravis, and uveitis.
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
Of patients who experienced relapse within 6 months of frontline treatment, 17% achieved a complete response.
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
Researchers summarized the novel techniques and models currently being developed to improve prognostication in diffuse large B-cell lymphoma.
Survivors treated with 2 different kinds of chemotherapy experienced similar general and mental health, activity limitations, and increase in risk for mortality,
Compared with white patients, Hispanic and non-Hispanic black patients had significantly poorer rates of postrelapse overall survival.
Early discontinuation of rituximab in patients with B-cell non-Hodgkin lymphoma was linked with worse survival.
In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.
A response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone appeared effective as a salvage therapy for follicular lymphoma.
The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors.
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
Improved rates of 3-year overall survival were seen in patients who were younger and who were diagnosed more recently.
Although gray zone lymphoma has distinct morphologic features, immunophenotyping can make classifying gray zone lymphoma challenging.
Risk for late-occurring thromboembolism was elevated in patients who underwent allogeneic transplantation, and risk factors varied by transplantation type.
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.
A global task force makes recommendations for safe and appropriate use.
Researchers conducted a meta-analysis of studies evaluating survival outcomes with rituximab plus chemotherapy with or without autologous HSCT.
Patients with positive interim PET/CT demonstrated poorer overall and progression-free survival compared with patients with negative interim PET/CT.
Researchers did not find a significant difference in survival outcomes for high- and low-risk patients with follicular lymphoma receiving immunotherapy.
Further investigations should look at the role of acquired BCL2 mutations in venetoclax resistance.
Survivors of NHL should be offered genetic counseling.
Researchers hypothesized that overlapping characteristics between autoimmune disease and NHL could be the result of similar genetic components.
The investigational treatment was associated with a high rate of neurotoxicity.
Fewer patients who experienced late relapse received upfront rituximab compared with patients who experienced early relapse.
Antibiotic treatment with carbapenem for
S. aureus infection was efficacious in patients with cutaneous T-cell lymphomas.
The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.
In a review article, researchers discussed how to maximize treatment efficacy while minimizing adverse effects for patients with mantle cell lymphoma.
Results from a phase 2 trial suggest that adding lenalidomide to follicular lymphoma treatment with rituximab may be efficacious.